Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01168713 · ClinicalTrials.gov registry record · Phase 2
Efficacy and Safety Study of Oral CEM-101 Compared to Oral Levofloxacin in Treatment of Patients With Community-Acquired Bacterial Pneumonia
A Phase 2 study, sponsored by Melinta Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 132
- Enrollment target
NCT01168713 is a Phase 2 study that has completed, run by Melinta Therapeutics. The registered enrollment target is 132 participants.
The verdict
NCT01168713, a Phase 2 study, has completed, sponsored by Melinta Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 132 participants
- Enrollment target
Study Summary
Study to evaluate the safety and efficacy of oral CEM-101 compared to oral Levofloxacin in the treatment of adults with moderate to moderately severe community-acquired bacterial pneumonia.
Interventions
- DRUG Levofloxacin
- DRUG CEM-101
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 132 participants |
| Start Date | 2010-08 |
| Est. Completion | 2011-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01168713
The ClinicalTrials.gov registry entry for NCT01168713 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 132 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Melinta Therapeutics, which has 31 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Levofloxacin is the first listed.
NCT01168713 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01168713 about?
NCT01168713 is a clinical study titled "Efficacy and Safety Study of Oral CEM-101 Compared to Oral Levofloxacin in Treatment of Patients With Community-Acquired Bacterial Pneumonia". Study to evaluate the safety and efficacy of oral CEM-101 compared to oral Levofloxacin in the treatment of adults with moderate to moderately severe community-acquired bacterial pneumonia.
What is the current status of trial NCT01168713?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 132 participants. The study started on 2010-08. Estimated completion is 2011-07.
What interventions are being tested in trial NCT01168713?
The interventions under investigation include: Levofloxacin (DRUG), CEM-101 (DRUG).
Who is sponsoring clinical trial NCT01168713?
This trial is sponsored by Melinta Therapeutics, which has 31 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.